Pharmaceutical cartel probe by Chinese regulator yields new individual penalty
A second individual has been penalized in China following a cartel investigation into a key drug raw material, this time involving a probe by the Tianjin antitrust regulator. Notably, in addition...To view the full article, register now.
Already a subscriber? Click here to view full article